🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Recruitingn/aAges 18 Years - anyAllIRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT06516406 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice. * Availability of data on clinical history prior to initiation of Ruxolitinib therapy * Obtaining informed consent for data collection and processing Exclusion Criteria: * None
💊

What it tests

  • Not listed
📍

Where

26 sites
Azienda Ospedaliera Annunziata
Cosenza, Italy
Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
Reggio Calabria, Italy
Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midollo
Naples, Italy
IRCCS Policlinico Sant'Orsola
Bologna, Italy
Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna
Ferrara, Italy
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy
AUSL di Piacenza - Palazzine Medicine Specialistiche
Piacenza, Italy
Dipartimento Oncoematologico - AUSL della Romagna
Ravenna, Italy

…and 18 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy